INFORMATION BY CANCER TYPE

Kidney

Expert Weighs in on Promising New Options for Frontline Kidney Cancer
BY Angelica Welch
David McDermott, M.D. discusses new advances made to treat kidney cancer. 
Kidney Cancer Trial Recommended to Halt
BY Silas Inman
An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open. 
Combination May Move to the Frontline for Kidney Cancer
A randomized trial showed that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) has some promise for the frontline treatment of some patients with RCC.
Durable Response Can Remain After Stopping Immunotherapy Treatment for Kidney Cancer
BY Lauren M. Green
A recent study found that patients with metastatic renal cell carcinoma may see extended response even after stopping immunotherapy treatment.
Antibiotics May Compromise Immunotherapy Efficacy in Kidney Cancer
BY Lisa Miller
Patients with metastatic kidney cancer may see a decreased efficacy of their immunotherapy regimen if they recently took antibiotics.
Sutent Treatment Breaks Are Feasible in Kidney Cancer
BY Danielle Bucco
Sutent treatment breaks seem to have no effect on clinical efficacy for patients with renal cell carcinoma.
Immune-Related Adverse Events Are Underreported in RCC
BY Angelica Welch
CURE spoke with Neeraj Agarwal, M.D., about the underreporting and underemphasizing of toxicities with PD-1 inhibitors in renal cell carcinoma.
Using Vaccines to Bolster Immunotherapy Responses in Kidney Cancer
BY Angelica Welch
Vaccines are currently being tested in their potential to improve immunotherapy responses for patients with renal cell carcinoma.
Immunotherapy Data is Encouraging in Kidney Cancer
BY Danielle Bucco
Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.
Combination Therapy Is Promising for Kidney Cancer, Expert Says
BY Danielle Bucco
David F. McDermott, M.D., is optimistic about combination regimens shaping the treatment landscape for renal cell carcinoma. 
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Kidney CURE discussion group.
Search Cancer Drugs & Terms